(Q38187476)

30 August 2017

title

The emerging role of carfilzomib combination therapy in the management of multiple myeloma (English)

1 reference

30 August 2017

Philippe Moreau

1

1 reference

30 August 2017

publication date

12 February 2014

1 reference

Expert Review of Hematology

30 August 2017

published in

1 reference

30 August 2017

volume

7

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

265-290

1 reference

Epidemiology of multiple myeloma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Treatment options for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Sequential or combination therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib combination therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Emerging biological insights and novel treatment strategies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Cure of myeloma: hype or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Can multiple myeloma become a curable disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Guidelines for the diagnosis and management of multiple myeloma 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.873699

10.1586/17474086.2014.873699

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference